The Insulin Cost Reduction Act

United States117th CongressHR-5623House of Representatives
Updated: Oct 20, 2021

Summary

The Insulin Cost Reduction Act This bill prohibits the negotiation of price concessions between insulin manufacturers and prescription drug plans under the Medicare prescription drug benefit unless the price concessions are either provided at the point of sale to beneficiaries or are reflected in cost-sharing requirements.

Bill texts

Available versions
Introduced (House)View official text

1 version available

All available records shown.

Timeline

  1. Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    House of Representatives

  2. Referred to the Subcommittee on Health.

    House of Representatives

  3. Introduced in House

  4. Referred to the Subcommittee on Health.

    House of Representatives

All available records shown.